Divis Labs gets no USFDA observations for Unit-I Telangana facility
"This is to inform that the Company's Unit-I facility at Lingojigudem, Bhuvanagiri Yadadri District, Telangana has been inspected by the USFDA," Divis Labs said in a filing.
New Delhi: Drug firm Divis Laboratories recently announced that it has received no observations from the US Food and Drug Administration (USFDA) after inspection of its Unit-I facility at Lingojigudem, Bhuvanagiri Yadadri District, Telangana.
The facility was inspected from 11th of November, 2019 to the 15th of November, 2019.
"This is to inform that the Company's Unit-I facility at Lingojigudem, Bhuvanagiri Yadadri District, Telangana has been inspected by the USFDA," Divis Labs said in a filing.
Also Read: Divis Labs gets 6 USFDA observations for Vizag unit
"This inspection was a general cGMP inspection by the US-FDA. The inspection has been concluded with no 483 observations, " The company added.
A Form 483 issued by the USFDA notifies the company’s management of objectionable conditions at its facility.
Read Also: Income Tax Department raids Divis Lab head office, manufacturing sites
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd